Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS C JONES

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1740208966
CMS profile
33174
Location
MACON, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,180.63

120 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,121.23 119
Gift $59.40 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS C JONES

NPI 1740208966 · CMS profile ID 33174

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

MACON, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740208966?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS C JONES, NPI 1740208966, CMS profile ID 33174. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740208966?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). THOMAS C JONES, NPI 1740208966, CMS profile ID 33174. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740208966?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
THOMAS C JONES, NPI 1740208966, CMS profile ID 33174, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1740208966?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

120 matching records · $2,180.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 120 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 120.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
IBSA Pharma Inc. $14.8808/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890030921 CMS
Tandem Diabetes Care, Inc. $12.0508/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963179365 CMS
Lilly USA, LLC $16.7508/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918371839 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.6508/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959664177 CMS
Abbott Laboratories $13.8707/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920557083 CMS
AstraZeneca Pharmaceuticals LP $11.8407/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915612033 CMS
Corcept Therapeutics $14.4207/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948791631 CMS
Novo Nordisk Inc $23.6707/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899486169 CMS
SANOFI-AVENTIS U.S. LLC $20.7407/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938773281 CMS
Xeris Pharmaceuticals, Inc. $21.5107/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946496221 CMS
Tandem Diabetes Care, Inc. $14.0707/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963179373 CMS
Bayer HealthCare Pharmaceuticals Inc. $12.2706/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929977029 CMS
Novartis Pharmaceuticals Corporation $15.2506/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893797185 CMS
Lilly USA, LLC $15.8706/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918371841 CMS
Esperion Therapeutics, Inc. $16.4206/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947262869 CMS
Bayer HealthCare Pharmaceuticals Inc. $14.9106/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930312173 CMS
Horizon Therapeutics plc $6.5806/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937639225 CMS
Horizon Therapeutics plc $122.0206/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937639223 CMS
Xeris Pharmaceuticals, Inc. $49.2606/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946496217 CMS
AstraZeneca Pharmaceuticals LP $15.6206/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915666719 CMS
Novo Nordisk Inc $18.1706/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898860515 CMS
Abbott Laboratories $13.6205/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920571397 CMS
Antares Pharma, Inc. $12.9405/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956848429 CMS
Horizon Therapeutics plc $17.8605/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937639221 CMS
Mannkind Corporation $59.4005/18/2022 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942758207 CMS
Novo Nordisk Inc $20.3805/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898556243 CMS
Novartis Pharmaceuticals Corporation $17.4005/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893797181 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $11.7005/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887503337 CMS
Bigfoot Biomedical Inc $18.9205/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957292817 CMS
Lilly USA, LLC $18.1705/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918316297 CMS
Bayer HealthCare Pharmaceuticals Inc. $14.0604/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930016179 CMS
Lilly USA, LLC $16.7504/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918316293 CMS
Zealand Pharma US, Inc. $18.2504/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905966805 CMS
Lilly USA, LLC $14.9904/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918321831 CMS
IBSA Pharma Inc. $13.9304/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890030917 CMS
Xeris Pharmaceuticals, Inc. $23.5204/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946496213 CMS
Novartis Pharmaceuticals Corporation $15.5904/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893797177 CMS
Amneal Pharmaceuticals LLC $13.6604/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956582741 CMS
Novo Nordisk Inc $21.4904/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898910461 CMS
Horizon Therapeutics plc $21.7003/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937639219 CMS
Zealand Pharma US, Inc. $18.2503/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905966809 CMS
Bayer HealthCare Pharmaceuticals Inc. $15.0003/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930337207 CMS
Xeris Pharmaceuticals, Inc. $7.0303/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946496209 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $11.8703/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887503339 CMS
Novartis Pharmaceuticals Corporation $14.6103/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893797173 CMS
Bigfoot Biomedical Inc $14.5303/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957292815 CMS
Lilly USA, LLC $16.5303/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918352051 CMS
Novo Nordisk Inc $18.8503/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898860523 CMS
Xeris Pharmaceuticals, Inc. $23.8103/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946496205 CMS
Zealand Pharma US, Inc. $18.2503/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905966803 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,504.96 167
PY2020 $3,776.80 77
PY2021 $20,016.68 160
PY2022 $2,180.63 120
PY2023 $1,976.86 110
PY2024 $1,733.33 89
PY2025 $1,512.05 80

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $748,464.14 38
PY2024 Recipient $34,366.00 2
PY2024 Principal investigator $1,107,182.83 26
PY2023 Recipient $1,258.37 3
PY2023 Principal investigator $1,096,099.07 18
PY2022 Recipient $27,506.00 2
PY2022 Principal investigator $336,350.74 19
PY2021 Recipient $49.59 1
PY2021 Principal investigator $733,693.30 31
PY2020 Recipient $2,343.50 1
PY2020 Principal investigator $389,736.03 22
PY2019 Recipient $7,570.43 2
PY2019 Principal investigator $388,900.97 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,612.00 12/31/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH JACKSONVILLE
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202532753
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 12/17/2025 Non-covered Recipient Entity
The Jones Center For Diabetes And Endocrine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220634935
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 12/17/2025 Non-covered Recipient Entity
The Jones Center For Diabetes And Endocrine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220634937
Principal investigator 1 ABBVIE INC. $6,382.60 12/05/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529306
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
The Jones Center For Diabetes And Endocrine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220634933
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 11/20/2025 Non-covered Recipient Entity
The Jones Center For Diabetes And Endocrine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220792915
Principal investigator 1 ABBVIE INC. $1,734.00 11/06/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202523207
Principal investigator 1 ABBVIE INC. $13,202.00 11/05/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521467
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
The Jones Center For Diabetes And Endocrine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220634925
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 11/01/2025 Non-covered Recipient Entity
The Jones Center For Diabetes And Endocrine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220634927
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 11/01/2025 Non-covered Recipient Entity
The Jones Center For Diabetes And Endocrine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220634929
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 11/01/2025 Non-covered Recipient Entity
The Jones Center For Diabetes And Endocrine
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220634931
Principal investigator 1 ABBVIE INC. $28,799.40 10/09/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202515367
Principal investigator 1 ABBVIE INC. $2,086.00 10/08/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202513537
Principal investigator 1 ABBVIE INC. $1,000.00 10/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202513451
Principal investigator 1 ABBVIE INC. $15,825.60 09/04/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509402
Principal investigator 1 ABBVIE INC. $10,961.00 08/27/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202505993
Principal investigator 1 ABBVIE INC. $15,244.60 08/06/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202502971
Principal investigator 1 ABBVIE INC. $16,643.20 07/02/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494809
Principal investigator 1 ABBVIE INC. $48,314.00 06/03/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202489307
Principal investigator 1 ABBVIE INC. $1,500.00 06/03/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202489321
Principal investigator 1 ABBVIE INC. $3,500.00 05/29/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202486923
Principal investigator 1 ABBVIE INC. $71,415.40 05/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483051
Principal investigator 1 Eli Lilly and Company $3,641.66 03/25/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187883906
Principal investigator 1 ABBVIE INC. $18,336.50 03/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202461407
Principal investigator 1 ABBVIE INC. $2,215.00 03/06/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202458797
Principal investigator 1 ABBVIE INC. $841.00 02/20/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202452915
Principal investigator 1 ABBVIE INC. $18,774.00 02/06/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202447837
Principal investigator 1 ABBVIE INC. $500.00 02/04/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202443748
Principal investigator 1 Eli Lilly and Company $150.00 01/31/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187880245
Principal investigator 1 Eli Lilly and Company $570.00 01/31/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1187883678
Principal investigator 1 Eli Lilly and Company $1,073.73 01/27/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187883904
Principal investigator 1 Eli Lilly and Company $27,863.00 01/21/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187883676
Principal investigator 1 Eli Lilly and Company $5,020.00 01/17/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY No dispute reported 06/30/2026 1187880401
Principal investigator 1 Eli Lilly and Company $82,860.00 01/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187878883
Principal investigator 1 Eli Lilly and Company $157,477.00 01/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187878885
Principal investigator 1 Eli Lilly and Company $41,626.00 01/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187879883
Principal investigator 1 Eli Lilly and Company $144,233.00 01/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1187883902